Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
RSVPreF3 + dTpa
- Development stage
- Unknown
- Lead developer
- GSK
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
RSVPreF3 + dTpa is a combination vaccine regimen consisting of the respiratory syncytial virus (RSV) fusion protein stabilized in the prefusion conformation (RSVPreF3) and the diphtheria, tetanus, and acellular pertussis vaccine (dTpa, marketed as Boostrix)[1][2][3]. RSVPreF3 is designed as a maternal vaccine to induce robust immune responses and prevent RSV-associated illness in infants, primarily via maternal antibody transfer[1][2][3]. dTpa provides immunity against diphtheria, tetanus, and pertussis and is routinely recommended for pregnant women to protect newborns from pertussis. The combination is administered intramuscularly and tested in phase 2 studies for its safety and immunogenicity in healthy women of childbearing age. Mechanistically, RSVPreF3 induces neutralizing antibodies against the RSV-F (fusion) protein and dTpa induces immune responses against diphtheria toxin, tetanus toxin, and pertussis antigens (pertussis toxin, filamentous hemagglutinin, and pertactin)[1][2][3].
- Brand names
- Boostrix
- Other names
- RSVPreF3 + dTpaRSVPreF3 coadministered with dTpaRSVPreF-3 coadministered with dTpaRSVPreF 3 coadministered with dTpaRSVPreF3 + Boostrix
02
Targets
RSV F (Respiratory syncytial virus fusion protein)Diphtheria toxin
Beyond the preview
Go deeper on RSVPreF3 + dTpa.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on RSVPreF3 + dTpa.